ASLN vs. GHSI, LGVN, MNPR, ADXN, MBIO, FLGC, AKTX, MYNZ, ERNA, and AEZS
Should you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Guardion Health Sciences (GHSI), Longeveron (LGVN), Monopar Therapeutics (MNPR), Addex Therapeutics (ADXN), Mustang Bio (MBIO), Flora Growth (FLGC), Akari Therapeutics (AKTX), Mainz Biomed (MYNZ), Eterna Therapeutics (ERNA), and Aeterna Zentaris (AEZS). These companies are all part of the "pharmaceutical preparations" industry.
ASLAN Pharmaceuticals (NASDAQ:ASLN) and Guardion Health Sciences (NASDAQ:GHSI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk.
ASLAN Pharmaceuticals presently has a consensus price target of $11.33, suggesting a potential upside of 1,742.22%. Given ASLAN Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ASLAN Pharmaceuticals is more favorable than Guardion Health Sciences.
58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.2% of Guardion Health Sciences shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Comparatively, 1.3% of Guardion Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ASLAN Pharmaceuticals received 135 more outperform votes than Guardion Health Sciences when rated by MarketBeat users. However, 67.39% of users gave Guardion Health Sciences an outperform vote while only 63.14% of users gave ASLAN Pharmaceuticals an outperform vote.
ASLAN Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Guardion Health Sciences has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.
Guardion Health Sciences has higher revenue and earnings than ASLAN Pharmaceuticals.
ASLAN Pharmaceuticals has a net margin of 0.00% compared to Guardion Health Sciences' net margin of -105.66%. Guardion Health Sciences' return on equity of -162.33% beat ASLAN Pharmaceuticals' return on equity.
In the previous week, ASLAN Pharmaceuticals had 5 more articles in the media than Guardion Health Sciences. MarketBeat recorded 8 mentions for ASLAN Pharmaceuticals and 3 mentions for Guardion Health Sciences. ASLAN Pharmaceuticals' average media sentiment score of 0.63 beat Guardion Health Sciences' score of 0.25 indicating that ASLAN Pharmaceuticals is being referred to more favorably in the media.
Summary
ASLAN Pharmaceuticals beats Guardion Health Sciences on 10 of the 15 factors compared between the two stocks.
Get ASLAN Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
ASLAN Pharmaceuticals Competitors List
Related Companies and Tools